Diamonds and Dogs
Kite Pharma is flying higher following better than expected earnings. Kite jumped 24% to a new 52 week high after beating earnings by a penny even as they missed on sales. Kite issued positive topline results from the primary analysis of the ZUMA-1 study of axicabtagene ciloleucel in patients with aggressive non-Hodgkin lymphoma (NHL). Analyst at H.C. Wainwright upgraded the stock with an $87 price target.
Target (TGT) misses the mark again. The retailer dropped 12% to a 52 week low and a three year low after missing earnings estimates even as sales were in-line. For the first quarter and the full year the company guided earnings well below consensus. The good news is the company's Internet sales have improved, but there seems to be an unexpected softness in store sales. The company understands that this new online shopping reality is where customers want to go. Amazon got another.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.